ESMO Preceptorship on Gastric Cancer 2023: Singapore

- Start date
- 29 Nov 2023
- End date
- 30 Nov 2023
- Location
- Singapore, Republic of Singapore
- Application deadline
- 21 Aug 2023 at 23:59 CEST
Learning Objectives
- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) and esophageal squamous cell cancers in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localised gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localised gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations, and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer
Download the preliminary programme
How to apply
Application is via online form. During the application process you will be required to upload the following:
- Your CV including a list of your publications
- 3-5 slides presenting a clinical case (please use the ESMO Preceptorship Case Presentation Power Point template, provided here)
Application deadline
Application for the course will close on 21 August 2023
Who can apply?
While this online course is primarily aimed at oncologists resident in the Asia-Pacific region, application is open to all ESMO members.
To apply, ESMO membership is mandatory. If you are not an ESMO member or need to renew your membership, please visit the ESMO membership pages.
ESMO COVID-19 Regulations
Each participant needs to check and comply with the latest health and travel regulations to ensure a fast and easy journey.
ESMO requires that all attendees are fully vaccinated against Covid-19 OR recovered in the last 6 months with at least one dose of a vaccine by the time of the meeting. Vaccination proof will not be checked by ESMO.
Additionally, we strongly recommend:
- Testing for Covid-19 within 48 hours prior to the inbound trip with a molecular, rapid antigen or self-test. The result will not be checked by ESMO
- Wearing a face mask in closed spaces
- Avoid shaking hands; wash your hands regularly and use hand sanitiser
The individual safety and hygiene measures of all participants are our priority, so we implemented additional measures on-site at the venue:
- Hand sanitiser will be available at the hotel
- Masks will be available on-site
- All surfaces will be disinfected on a regular basis
Any changes to the COVID-19 regulations will be communicated on this webpage
Insurance
ESMO bears no responsibility for any untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel coverage
What's included?
Successful applicants will benefit from complimentary course registration and accommodation.
Travel Grant
In addition to the course registration and the hotel accommodation, a travel grant of maximum 600 euros is offered to selected applicants as a contribution versus their travel costs. The reimbursement will be processed after the course against original invoices/vouchers. Please be aware that visa costs are NOT covered by the travel grant and are the participant's responsibility.
Accreditation
The programme of this event will has been accredited with 8 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs:
- Hanneke van Laarhoven, Netherlands
- Matthew C. H. Ng, Singapore